Status:
UNKNOWN
Real-world Data Regarding Treatment of Ulcerative Colitis Patients With Golimumab
Lead Sponsor:
University of Zurich
Conditions:
Ulcerative Colitis
Flare Up, Symptom
Eligibility:
All Genders
Brief Summary
TNF inhibitors have improved treatment options for patients with inflammatory bowel disease (IBD) and three TNF inhibitors, infliximab, adalimumab and golimumab are available for treatment of ulcerati...
Detailed Description
Ulcerative colitis patients from the Swiss IBD cohort study treated with golimumab will be identified. The investigators will perform a retrospective chart review and assess patient reported outcomes ...
Eligibility Criteria
Inclusion
- Patient of the Swiss IBD cohort study
- Diagnosis ulcerative colitis
- Past treatment with golimumab (at least one dose)
Exclusion
- none
Key Trial Info
Start Date :
January 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2018
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT03394586
Start Date
January 1 2018
End Date
December 31 2018
Last Update
January 9 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Division of Gastroenterology, University Hospital Zurich
Zurich, Switzerland, 8091